Premium
Anjan Drug, a PAG-backed active pharmaceutical ingredient (API) manufacturer, reported a decline in revenue for the fiscal year ended March 31, 2025, according to provisional financials reviewed by VCCircle. The Chennai-based company’s revenue from operations fell 11% year-on-year to Rs 289 crore ($33.7 million) in FY25, primarily due to softening demand ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
